Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-01
DOI
10.1038/s41571-021-00492-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
- (2021) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Single cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment
- (2020) Anuja Sathe et al. CLINICAL CANCER RESEARCH
- Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
- (2020) E. Van Cutsem et al. EUROPEAN JOURNAL OF CANCER
- A phase II study of futibatinib (TAS-120) in patients (pts) with advanced (adv) solid tumors harboring fibroblast growth factor receptor (FGFR) genomic aberrations.
- (2020) Antoine Hollebecque et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
- (2020) Richard T. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas.
- (2020) S. Derks et al. ANNALS OF ONCOLOGY
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer
- (2020) Yohei Kubota et al. CLINICAL CANCER RESEARCH
- The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B–NTRK1 fusion
- (2020) Aya Shinozaki-Ushiku et al. Gastric Cancer
- Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
- (2020) Daniel V.T. Catenacci et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.
- (2020) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.
- (2020) Kohei Shitara et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
- (2020) Anita Kulukian et al. MOLECULAR CANCER THERAPEUTICS
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1, First-in-Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1–4 Inhibitor in Patients with Advanced Solid Tumors
- (2020) R. Bahleda et al. ANNALS OF ONCOLOGY
- Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
- (2020) Akihito Kawazoe et al. LANCET ONCOLOGY
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
- (2020) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- (2020) Susan M Domchek et al. LANCET ONCOLOGY
- MET-dependent solid tumours — molecular diagnosis and targeted therapy
- (2020) Robin Guo et al. Nature Reviews Clinical Oncology
- 1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
- (2020) K. Yamaguchi et al. ANNALS OF ONCOLOGY
- 1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062
- (2020) L.S. Wyrwicz et al. ANNALS OF ONCOLOGY
- LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
- (2020) N. Boku et al. ANNALS OF ONCOLOGY
- LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
- (2020) M. Moehler et al. ANNALS OF ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
- (2020) Yoshiaki Nakamura et al. NATURE MEDICINE
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
- (2020) Daniel V.T. Catenacci et al. Cancer Discovery
- Proteogenomic Characterization of Human Early-Onset Gastric Cancer
- (2019) Dong-Gi Mun et al. CANCER CELL
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).
- (2019) Daniel V.T. Catenacci et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
- (2019) Manish A. Shah et al. Gastric Cancer
- Enrichment of CLDN18 -ARHGAP fusion gene in gastric cancers in young adults
- (2019) Izuma Nakayama et al. CANCER SCIENCE
- Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase 3 study design
- (2019) Daniel VT Catenacci et al. Future Oncology
- Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma.
- (2019) Xianbao Zhan et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
- (2019) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- FRI-471-Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization
- (2019) Chia-Wei Chen et al. JOURNAL OF HEPATOLOGY
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- (2019) O Türeci et al. ANNALS OF ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
- (2019) Aparna R. Parikh et al. NATURE MEDICINE
- [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model
- (2019) Tomomi Nakayama Iwata et al. PLoS One
- HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
- (2019) Akio Kaito et al. World Journal of Clinical Cases
- Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer
- (2019) Haisheng Zhang et al. Cancer Discovery
- Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
- (2018) S T Kim et al. ANNALS OF ONCOLOGY
- Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
- (2018) Yang Liu et al. CANCER CELL
- Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion
- (2018) Bharat K.R. Chaganty et al. CANCER LETTERS
- The Cancer Genome Atlas: Creating Lasting Value beyond Its Data
- (2018) Carolyn Hutter et al. CELL
- Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
- (2018) Takeru Wakatsuki et al. JOURNAL OF GASTROENTEROLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
- (2018) Yongjun Cha et al. Molecular Oncology
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
- (2018) Yoshiaki Nakamura et al. ONCOLOGIST
- Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma
- (2018) Steven B. Maron et al. Cancer Discovery
- E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer
- (2018) Ilirjana Bajrami et al. Cancer Discovery
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
- (2018) Clara Montagut et al. JAMA Oncology
- Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
- (2018) De-Shen Wang et al. GUT
- The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).
- (2018) Satoshi Yuki et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- 103PPrevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples
- (2018) D Moran et al. ANNALS OF ONCOLOGY
- 83POlaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
- (2018) Y-Z Liu et al. ANNALS OF ONCOLOGY
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
- (2018) K Muro et al. ANNALS OF ONCOLOGY
- A Multicenter Phase 2 Study of AMG 337 in Patients With MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other Solid Tumors
- (2018) Eric Van Cutsem et al. CLINICAL CANCER RESEARCH
- Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
- (2018) Shusuke Yagi et al. Gastric Cancer
- Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
- (2018) Seyoung Seo et al. Gastric Cancer
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
- (2018) Alicia Latham et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
- (2018) Francisco Sanchez-Vega et al. Cancer Discovery
- Genomic loss of heterozygosity and survival in the REAL3 trial
- (2018) Elizabeth C. Smyth et al. Oncotarget
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
- (2017) Yasutoshi Kuboki et al. Gastric Cancer
- Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers
- (2017) Soo Young Cho et al. GASTROENTEROLOGY
- Germline Mutations in PALB2 , BRCA1 , and RAD51C , Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer
- (2017) Ruta Sahasrabudhe et al. GASTROENTEROLOGY
- Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
- (2017) Russell D. Petty et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
- (2017) Prabhsimranjot Singh et al. Journal of Hematology & Oncology
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Yung-Jue Bang et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2–Amplified Gastric Cancer Patient–Derived Cell Model
- (2017) Jiryeon Jang et al. Translational Oncology
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
- (2017) Yelena Y. Janjigian et al. Cancer Discovery
- Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
- (2017) Eirini Pectasides et al. Cancer Discovery
- Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients
- (2017) Jiwon Koh et al. Oncotarget
- Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
- (2017) Manish A. Shah et al. JAMA Oncology
- Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability
- (2016) Changqing Ma et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
- (2016) Charles S Fuchs et al. BRITISH JOURNAL OF CANCER
- Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
- (2016) V. Varadan et al. CLINICAL CANCER RESEARCH
- Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
- (2016) Sook Ryun Park et al. EUROPEAN JOURNAL OF CANCER
- Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients
- (2016) Akihito Kawazoe et al. Gastric Cancer
- HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
- (2016) F. Pietrantonio et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
- (2016) A. Pearson et al. Cancer Discovery
- Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas
- (2016) Jia-Bin Liao et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases
- (2015) Rocco Cappellesso et al. HUMAN PATHOLOGY
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
- (2015) Razvan Cristescu et al. NATURE MEDICINE
- Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis
- (2015) FEI YUAN et al. ONCOLOGY REPORTS
- A mutational signature in gastric cancer suggests therapeutic strategies
- (2015) Ludmil B. Alexandrov et al. Nature Communications
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
- (2015) E. L. Kwak et al. Cancer Discovery
- Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
- (2015) Sangjeong Ahn et al. Oncotarget
- Gastrointestinal malignancies harbor actionable MET exon 14 deletions
- (2015) Jeeyun Lee et al. Oncotarget
- Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity
- (2015) Fei Yao et al. Cell Reports
- Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract
- (2015) Olatunji B. Alese et al. Therapeutic Advances in Medical Oncology
- The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
- (2015) Ji Yun Lee et al. Scientific Reports
- Prognostic Impact of Major Receptor Tyrosine Kinase Expression in Gastric Cancer
- (2014) Yukinori Kurokawa et al. ANNALS OF SURGICAL ONCOLOGY
- Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
- (2014) Lin Shen et al. Gastric Cancer
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer
- (2014) Yukinori Kurokawa et al. Gastric Cancer
- Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma
- (2014) Akiko Kawano Nagatsuma et al. Gastric Cancer
- Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
- (2014) Suling J Lin et al. GUT
- Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status
- (2014) Tao Wang et al. HUMAN PATHOLOGY
- Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
- (2014) Jihun Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
- (2014) Susan J Dutton et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
- (2013) N C T van Grieken et al. BRITISH JOURNAL OF CANCER
- Identification ofROS1rearrangement in gastric adenocarcinoma
- (2013) Jeeyun Lee et al. CANCER
- Physiological roles of Rho and Rho effectors in mammals
- (2013) Dean Thumkeo et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Improved survival of gastric cancer with tumour Epstein–Barr virus positivity: an international pooled analysis
- (2013) M Constanza Camargo et al. GUT
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions
- (2013) Nicola Fusco et al. MODERN PATHOLOGY
- Epstein-Barr Virus Infection as an Epigenetic Driver of Tumorigenesis
- (2012) A. Kaneda et al. CANCER RESEARCH
- Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
- (2012) Hee Eun Lee et al. EUROPEAN JOURNAL OF CANCER
- Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas
- (2012) Matteo Fassan et al. HUMAN PATHOLOGY
- Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma
- (2012) Eun-Jung Jung et al. HUMAN PATHOLOGY
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas
- (2012) Eun Yoon Cho et al. MODERN PATHOLOGY
- Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
- (2011) C Bozzetti et al. BRITISH JOURNAL OF CANCER
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections*
- (2011) Stephen Lee et al. HISTOPATHOLOGY
- Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma
- (2011) Min A Kim et al. HISTOPATHOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 status in unusual histological variants of gastric adenocarcinomas
- (2011) Giuseppe Giuffrè et al. JOURNAL OF CLINICAL PATHOLOGY
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HER2 Testing in Gastric Cancer
- (2010) Luca Albarello et al. ADVANCES IN ANATOMIC PATHOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Microsatellite instability in colorectal cancer—the stable evidence
- (2010) Eduardo Vilar et al. Nature Reviews Clinical Oncology
- HER-2 amplification is highly homogenous in gastric cancer
- (2009) Andreas H. Marx et al. HUMAN PATHOLOGY
- PARP-1 Inhibition Prevents Oxidative and Nitrosative Stress–Induced Endothelial Cell Death via Transactivation of the VEGF Receptor 2
- (2008) Marlene T. Mathews et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now